INTRODUCTION
Ketamine is one of the general anesthetics with both sedativehypnotic and analgesic properties. 1 It is water-and fat-soluble and produces unconsciousness in 30 to 60 seconds and a quick recovery within 20 minutes after one bolus of intravenous injection. 2 It is metabolized by microsomal cytochrome P450 enzymes in the liver with elimination half-life of 2 hours. [1] [2] [3] Except for the advantages of rapid onset, short-term effect, ketamine has properties of cardiovascular excitation and alleviation of bronchospasm by sympathomimetic activities, thus it is widely used in clinical pediatric, asthmatic, or critical patients for surgery. In recent years, a low dose of ketamine has increasingly been used to treat acute pain in perioperative period [3] [4] [5] and chronic pain. 6 Moreover, clinical studies have demonstrated that a single subanesthetic dose of the ketamine mediates rapid antidepressant effect in patients with therapy-resistant depression. 7 Musk, known as a highly valued ingredient of Chinese medicinal remedies, has been widely used in China for the treatment of sprains and fractures, cardiovascular, and cerebrovascular diseases. [8] [9] [10] In current traditional Chinese medicine, natural musk has been replaced mostly with its chemically synthesized counterparts. Muscone, chemical structure is 3-methylcyclopentadecanone, is one of the macrocyclic musk compounds and primarily responsible for the characteristic odor of musk. As the main active ingredient of musk, muscone is verified to have protective effects on varieties of diseases such as myocardial infarction, cerebral ischemia, acute kidney injury, edema and alcohol-induced osteonecrosis, etc, with less toxicity and side effects. 11, 12 The mechanism underlying protective effects includes inhibiting cell apoptosis and inflammation, 13, 14 attenuating calcium influx and oxidative stress, 15 promoting angiogenesis by activation of vascular endothelial growth factor expression, 16 etc.
An increasing number of patients with cardiovascular or cerebral diseases receive muscone treatment in China. Muscone have been showed to permeate the blood-brain barrier in some experimental models. 17 Since the effective site of general anesthetics is also brain, it is possible that muscone will affect the Abstract Background: The aim of this study was to determine the effects of different concentrations of muscone on the ketamine requirement for hypnosis and analgesia and possible mechanism in mice. Methods: In the hypnotic response experiment, muscone (0.5, 1.0, 2.0, 4.0, and 8.0 mg/kg) was administered 15 minutes before ketamine by intraperitoneal injection. The hypnotic response was evaluated by loss of righting reflex (LORR). In the analgesia experiment, muscone (0.5, 1.0, 2.0, and 4.0 mg/kg) was administered 15 minutes before 50 mg/kg ketamine injection. Pain threshold was assessed by measuring the tail-flick latency induced by heat radiation. Twenty minutes after ketamine injection, the mRNA expression of N-methyl-d-aspartate receptors (NR) subunits, γ-aminobutyric acid (GABA) receptors subunits, opioid receptors subunits, and some Na + and Ca 2+ channels were detected by qPCR in the hippocampus of mice. Results: The 50% effective dose (ED 50 ) with 95% confidence interval of ketamine-induced LORR was 49.2 (43.4-56.4) mg/kg. About 4.0 or 8.0 mg/kg muscone increased ED 50 of ketamine-induced hypnosis, which was 82.7 (70.0-98.4) mg/kg or 72.0 (65.4-85.7) mg/kg, respectively. In the analgesic experiment, ketamine alone caused an obvious analgesic effect, whereas different dose of muscone decreased pain threshold in the presence of ketamine; 4.0 mg/kg muscone up-regulated the mRNA expression of NR1 and inhibited ketamine-induced increase of δ-opioid receptor mRNA level. Muscone also inhibited Cav2.1 mRNA expression in the presence of ketamine. Conclusion: Muscone reduced the hypnotic and analgesic effect of ketamine in dose-independent manner in mice, which may be related to the changes of NR1 and δ-opioid receptor.
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Original Article. (2020) 83:2 J Chin Med Assoc potency of general anesthetics if muscone is administered before anesthesia and surgery. Our recent study has found that ligustrazine, another ingredient extracted from Chinese herb, enhanced the hypnotic and analgesic effect of ketamine in mice. 18 The present study is to explore whether and how muscone influences the hypnotic and analgesic effects of ketamine in mice.
METHODS

Animals
This study was approved by the animal care committee at Sun Yat-sen University and performed in accordance with the National Institutes of Health Guide for the Use of Laboratory Animals. A total of 168, four-month-old C57BL/6 male mice (Guangdong Medical Laboratory Animal Co., China, permission number: SCXK20160029) weighing 22 to 25 g were used in this study. These mice were kept in plastic sawdust floor cages in-house and maintained under controlled environmental conditions on a 12:12 constant light-dark cycle at constant temperature (22ºC) with free access to food and water.
Experimental protocol
Muscone and ketamine hydrochloride were freshly prepared in 0.9% saline on the day of the experiment and administered in a volume of 0.1 ml per 10 g of body weight intraperitoneally. Hypnotic effect of ketamine was measured by loss of righting reflex (LORR) via up-and-down sequential method and the analgesic effect was evaluated by tail-flick latency induced by heat radiation. In the hypnotic effect experiment, mice were administered saline or five doses of muscone (0.5, 1.0, 2.0, 4.0, and 8.0 mg/kg) 15 minutes before ketamine (n = 12-16 in each group). The effects of different doses of muscone on the median effective dose (ED 50 ) of ketamine-induced LORR were determined. Another group of mice were administrated with 8.0 mg/kg muscone without ketamine (n = 10) to test whether muscone alone have hypnotic effect. In the analgesic effect experiment, saline or four doses of muscone (0.5, 1.0, 2.0, and 4.0 mg/kg) were injected intraperitoneally 15 minutes before administration of 50 mg/kg ketamine (n = 10). Saline control group received saline for two times and muscone control group received 4 mg/kg muscone and saline to evaluate the analgesic effects of muscone alone (n = 10). In a separate experiment, mice received normal saline or 4 mg/kg muscone intraperitoneally 15 minutes before ketamine injection. The dose of ketamine was the ED 50 value for it hypnotic effect when given 4.0 mg/ kg muscone, which determined by above experiments. Twenty minutes after ketamine injection, mice were sacrificed and their hippocampus were taken for detecting the mRNA expression of N-methyl-d-aspartate (NMDA) receptors (NR) subunits, γ-aminobutyric acid (GABA) receptors subunits, opioid receptors subunits, and some Na + and Ca 2+ channels by polymerase chain reaction (PCR) (n = 4).
Losing of righting reflex determination
The sedative effect of ketamine was assessed by LORR as we described before. 18 In brief, mice were placed in the supine position in a circular glass beaker immediately following administration of ketamine or saline. The beaker was kept horizontally on a shelf and rotated slowly. LORR was defined as no righting within 10 seconds. The starting time and the duration of LORR were assessed and recorded for 10 minutes by a blinded observer.
Determining ED 50 of ketamine for hypnotic effect
The up-and-down sequential method of Dixon and Mood was used to determine the ED 50 of ketamine for its hypnotic effect in this study. Dixon's up-and-down method is a classic pharmacology trial to determine ED 50 by performing sequential design for dosage. The first dose administrated usually gets from the primary experiment and should be as close as 16.47, and 11.5 mg/kg and the first dose in each group is 48 mg/ kg as we described before. 18 The dosing administrated to the next mouse was adjusted by reaction of the former mouse. LORR was defined as positive response after administration of ketamine. If the response of the former mouse was positive, the ketamine dose given to the next mouse was decreased to a lower gradient; otherwise increased to a higher gradient. The experiments for each group will be terminated till achieving five positive-negative crossovers.
Tail-flick test
The response to pain of mice was tested by a tail-flick apparatus (IITC Life Science Series 8, USA) as described in our previous study. 18 The latency of tail-flick in reaction to noxious skin heating was recorded as the pain threshold. The pain latencies were recorded 15 minutes before muscone administration (baseline latencies) and 5, 15, 30, and 60 minutes after ketamine administration. Each mouse was measured for three times with 30 seconds interval at every time point and the latencies were considered as the mean of three measurements. A cut-off exposure time of 10 seconds was set to avoid damaging the tail. Supplementary Table 3 .
Data analysis
The sample size for evaluating ED 50 of ketamine-induced hypnosis was determined by five independent pairs of mice with positive/negative LORR according to up-and-down method of Dixon, and it is 12-16 mice in each group according to the actual experiments. The sample size for evaluating pain threshold was calculated based on a statistical power of 80% with a two-sided significance level of 0.05 using the PASS 11 software. All analyses were performed using the Statistical Package for the Social Sciences (SPSS 22). The ED 50 value with 95% confidence interval (CI) of ketamine-induced hypnosis was calculated with two methods: Dixon and Massey up-and-down method and probit analysis. Probit analysis was also used to calculate the ED 95 with 95% CI and estimate the curves of the dose-response relations for the hypnotic effect of ketamine. Tail-flick latency is presented as mean ± SD and analyzed by repeated-measure of ANOVA followed by the Tukey post-hoc test. The mRNA expression was analyzed by one-way ANOVA followed by the Tukey post-hoc test. p < 0.05 was considered statistically significant.
RESULTS
Large dose of muscone increased the ED50 of ketamine for hypnosis in mice
Dose-response data were illustrated in Fig. 1 . Mice with administration of large dose of muscone (8.0 mg/kg) alone did not induce LORR until 10 minutes, and these data are not shown in Figure 1 Figure 2A ). Small doses of muscone (0.5-2.0 mg/kg) showed no effect on the ED 50 value of ketamine-induced LORR in mice and the dose-effect curves almost coincided to that of ketamine alone ( Figure 2B ). Large doses of muscone (4.0 and 8.0 mg/ kg) increased the ED 50 and ED 95 value of ketamine-induced LORR than ketamine alone in mice (p < 0.05) ( Table 1 ).
The dose-effect curves of mice pretreating 4.0 and 8.0 mg/kg muscone were shifted to the right, suggesting that more than 4.0 mg/kg muscone reduces ketamine-induced hypnotic effect. There was no significant difference between 4.0 and 8.0 mg/kg muscone in ED 50 and ED 95 value, which suggested that muscone inhibiting ketamine-induced hypnotic effect was not in dosedependent way.
Muscone decreased pain threshold and reduced ketamine-induced analgesic effects in mice
The tail-flick latencies of mice in seven groups before and after muscone and/or ketamine were shown in Table 2 . The results of repeated measures ANOVA indicated that test time had significant effects on tail-flick latency (F = 11.460, p < 0.05). Ketamine or muscone also had significant effects on tail-flick latency (F = 2.490, p < 0.05). Besides, there was no cross interaction among time, ketamine, and muscone (F = 0.473, p = 0.755). The baseline values of tail-flick latency showed no significant difference among all the groups. Compared to baseline values, tail-flick latency did not change over time in normal saline group and 4.0 mg/ kg muscone group, which suggested normal saline and muscone itself did not change pain threshold. Ketamine increased tailflick latency at 5 and 15 minutes (p < 0.05), which suggested ketamine has analgesic effects. Compared to ketamine alone, pretreatment of muscone at different dose (0.5-4.0 mg/kg) reduced tail-flick latency of mice at 5 and 15 minutes (p < 0.05). The tail-flick latency did not show significant differences among four groups pretreated with different dose of muscone, which suggested muscone reduces ketamine-induced analgesia in doseindependent way.
3.3. Muscone increased NR1 mRNA, inhibited ketamineinduced δ-opioid receptors mRNA increase, and reduced Cav2.1 mRNA in the presence of ketamine in the hippocampus of mice The ED 50 value of ketamine-induced LORR when given 4.0 mg/ kg muscone was 82.7 (70.0-98.4) mg/kg in mice, according to previous experiment. Therefore, 83 mg/kg ketamine was used to explore the possible mechanism of muscone affecting ketamine. The mRNA expression of NR2A, NR2B, NR2C, NR3A, and NR3B showed no difference among all groups (Fig. 3B-F) . Ketamine alone did not change NR1 mRNA level, whereas muscone alone significantly up-regulated the expression of NR1 mRNA, compared with control ( Fig. 3A , p < 0.01). Moreover, after ketamine anesthesia, muscone still increased NR1 mRNA level compared with ketamine alone group (Fig. 3A , p < 0.05). Neither ketamine nor muscone influenced the mRNA expressions of the GABA A 1 or GABA A 2 receptor (Fig. 4A , Table 1 The effects of muscone on ED 50 and ED 95 B). As to opioid receptor, ketamine increased δ-opioid receptor transcription (Fig. 4E , p < 0.01), which was recovered by pretreatment of muscone ( Fig. 4E, p < 0.05) . The levels of μand κ-opioid receptors mRNA had no differences among all groups (Fig. 4C, D) . Muscone significantly decreased the level of Cav2.1 mRNA after ketamine anesthesia, although ketamine alone did not change the mRNA level of Cav2.1 (Fig. 5A , p < 0.05). The level of Cav2.2 and Nav1.1 mRNA was similar among all groups (Fig. 5B, C) .
DISCUSSION
The present study showed that large doses of muscone increased the ED 50 of ketamine to induce LORR and inhibited hypnotic effect of ketamine. Moreover, muscone reduced ketamine-induced analgesic effect in dose-independent way. These results indicate that muscone attenuates the hypnotic and analgesic roles of ketamine. Ketamine, as a nonspecific NMDA receptor antagonist, provides powerful sedation and analgesia within few minutes. Excepting for NMDA receptor, multiple receptors channels including GABA, opioid and nicotinic acetylcholine, glycine, and Na + and Ca 2+ channels are involved in ketamine-induced sedation and analgesia. [19] [20] [21] GABA A receptor plays critical roles in the mechanism of hypnosis. Intravenous anesthetics, like pentobarbital, propofol, ketamine, or inhalational anesthetics induced hypnosis mainly by activating inhibitory GABA A receptor or increasing the sensitivity of GABA A receptor. 22, 23 Our present results showed that the ED 50 value for ketamine to induce LORR was 49.3 (39.1-62.1) mg/kg in mice, which was similar to the value from probit analysis [49. 2 (43.4-56.4 ) mg/kg]. The ED 50 value in our study was a little lower than our previous study that is 54.1 (38.4-76.1) mg/kg. 18 The difference of results in two studies was less than 5%, which is the acceptable variation. Another reason was that we used five positive-negative crossovers to evaluate ED 50 value in the present study, and the precision of results is improved compared to our previous study, which used four positivenegative crossovers. 18 The mice received muscone >4 mg/kg in advance, required significantly higher ED 50 and ED 95 concentrations of ketamine to lose their righting reflexes, whereas 8 mg/kg muscone did not further increase the requirement of ketamine than 4 mg/kg muscone, suggesting that muscone reducing the sensitivity of mice in ketamine-induced hypnosis was not in a dose-dependent way. Our results were consisted with the previous study, which reported that muscone shortened sleep time Fig. 4 The mRNA levels of γ-aminobutyric acid (GABA) A and opioid receptors determined by qPCR in the hippocampus of mice. Mice received normal saline or induced by sodium pentobarbital, another intravenous general anesthetic, in mice. 24 The mechanism of muscone-resisted ketamine-induced hypnosis is undermined. Ketamine has GABA A receptor agonistic properties and ketamine-induced hypnosis is partly mediated by GABA A receptors. 19 Our present results showed neither ketamine nor muscone did not change the level of GABA A 1 and GABA A 2 mRNA in the hippocampus of mice, which suggested ketamine modulated GABA A receptor function without influence of GABA A receptor gene transcription. It is reported that muscone also reduces the hypnotic effect of pentobarbital, another anesthetics, which exerts sedation by specific activation of GABA A receptor. 24 It is possible muscone blocks the activity of GABA A receptor or decreases the sensitivity of GABA A receptor. In addition, antagonism of NMDA receptor was also involved in ketamine-induced hypnosis. 25 Our results showed ketamine did not change mRNA expression of NR1, NR2A, NR2B, NR2C, NR3A, NR3B in the hippocampus of mice, whereas muscone significantly increased NR1 mRNA level with or without ketamine administration. Increase of NR1 mRNA may contribute to synthesis of more NR1 protein and upregulation of activity of NMDA receptor, which may be one of reason that muscone attenuates ketamine-induced hypnosis.
The influence of muscone on analgesic effects of ketamine is obvious. In the heat radiant tail-flick test, muscone alone did not influence pain threshold. However, it reduced ketamineinduced analgesia even at low dose (0.5 mg/kg) and the antianalgesia effect is dose-independent. The analgesic mechanism of ketamine is mainly related to blocking NMDA receptors in the peripheral and central nervous system. 26 It is possible that muscone attenuates effect of ketamine-induced analgesia by increase of NR1 mRNA level and upregulation of activity of NMDA receptor. On the contrary, analgesia induced by ketamine is partially mediated by opiate mechanisms. Endogenous opioids and μ-and δ-opioid receptors, not κ-opioid receptors, are involved in ketamine-induced central antinociception. 27 Our present results showed ketamine increased mRNA level of δ-opioid receptors, which was inhibited by pretreatment of muscone, indicating that δ-opioid receptor may be also involved in anti-analgesic effects of muscone in hippocampus of mice. Although ketamine did not change mRNA level of μ-opioid receptors, it could be functional interaction with μ-opioid receptors and promotes analgesic effect. 28 Whether muscone disturbs μ-opioid receptors function need further study. In addition, the voltage-gated calcium channels and voltage-gated sodium channels play key roles in cell membrane stability and chronic pain. Our present results showed that ketamine or muscone alone did not influence mRNA level of Cav2.1, Cav2.2, and Nav1.1. However, muscone reduced expression of Cav2.1 mRNA in the presence of ketamine. Cav2.1 plays an essential role in the presynaptic modulation of neurotransmitter release 29 and maintains synaptic homeostasis. 30 Inhibition of presynaptic Cav2.1 functions reduces glutamate (one of the NMDA agonists) release in the hippocampus. Muscone upregulation of NR1 mRNA level may enhance glutamate effect, whereas NMDA receptor was blocked under ketamine anesthesia. It is presumable that reduction of Cav2.1 mRNA is adaptation of homeostatic regulation of glutamate release in the presence of muscone and ketamine. The detail mechanism needs further study. Our previous study demonstrated ligustrazine, another Chinese medicine, strengthens the hypnotic role of ketamine at a low dose and promotes the analgesic effect of ketamine at a large dose in mice. 18 Although both ligustrazine and muscone were used in patients with cardiovascular or cerebral diseases and proved to exert potent protective activities on myocardial or cerebral ischemia experimental model, 11, [31] [32] [33] [34] the influence of ligustrazine and muscone on hypnotic and analgesic effects of ketamine are totally different. These results reminded us to attach importance to the effects of Chinese medicine on anesthetics since Chinese medicine were used more and more popular in clinic.
In conclusion, we found that muscone reduced the hypnotic and analgesic effect of ketamine in dose-independent manner in mice, which may be related to the changes of NR1 and δ-opioid receptor. These results suggest muscone may alleviate anesthesia potency of ketamine in mice. Although whether muscone has similar influence on human being or on other anesthetics is underdetermined, it is important to monitor anesthesia depth during anesthesia and surgery in case that intraoperative awareness occurs if patients were administrated with muscone before surgery.
